Stay updated on SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.

Latest updates to the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page
- CheckyesterdayChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check44 days agoChange DetectedRevision: v3.4.3 implemented. No visible changes to study data, eligibility criteria, or study details.SummaryDifference0.0%

- Check65 days agoChange DetectedRevision label updated from v3.4.1 to v3.4.2; no study data or page functionality appears to be altered.SummaryDifference0.0%

- Check73 days agoChange DetectedAdded Primary peritoneal carcinoma to the conditions, introduced a Resources section with the Genetic and Rare Diseases Information Center, and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.2%

- Check88 days agoChange DetectedAdded Show glossary and Hide glossary controls, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0; removed Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.3%

Stay in the know with updates to SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.